Elisabeth Quoix MD
Professor Emeritus of the University of Strasbourg, FranceElisabeth Quoix is Professor of Pneumonology in the Department of Chest Diseases of the University Hospital of Strasbourg. Her clinical work focuses on the diagnosis and management of lung cancer, including the use of chemotherapy. She was a resident at the Strasbourg University hospital (1976–1980) and received her medical degree from Strasbourg, Louis Pasteur University in 1980, after which she became “Chef de Clinique-Assistant des Hôpitaux” until 1984. She then spent several months at the McGill Cancer Center of Montreal (Quebec, Canada) as a research assistant, where she participated in research on the design and methodology of clinical trials, including the impact of biases and assessment of response. In 1985 she was appointed “Praticien Hospitalier” at the University Hospital of Strasbourg, and was nominated as a Professor in 1990. She was Head of the Department of Pneumology until September 1st 2018 when she became "Consultante" in the University Hospital of Strasbourg.
Dr. Quoix was the secretary of the “Groupe d’Oncologie Thoracique” of the French Society of Pneumonology (1992–1995) and was the first President of the IFCT (French Intergroup of Thoracic Oncology) from its creation in 1999 until 2006. She is a now Past-President and the secretary of the Scientific Council of the IFCT.
Dr. Quoix was involved as an investigator or coordinator in several academic trials investigating treatment strategies in lung cancer, through IFCT, with a special focus on elderly patients as well as in a number of early phase trials of novel agents for lung cancer, with pharmaceutical industry sponsorship. She is also involved in epidemiological studies of the implementation of “state of the art” techniques of diagnosis and treatment among the general population of patients with lung cancer. Dr. Quoix is the author or co-author of more than 290 peer-reviewed papers, mainly in the field of lung cancer. She had contributed to several textbooks on the subject of pneumonology and lung cancer.
She is now Professor Emeritus of the University of Strasbourg
Disclosures
Dr. Quoix is the coordinating investigator of an academic trial conducted with IFCT investigating the role of chemotherapy alone versus chemotherapy + immunotherapy (atezolizumab) in elderly patients with advanced non-small cell lung cancer.
Recent Contributions to PracticeUpdate:
- Risk of Lung Cancer Among Smokers in Whom Annual Screening Is Not Recommended
- Addition of Bevacizumab to Erlotinib as First-Line Treatment for EGFR-Mutated Advanced Nonsquamous NSCLC
- Effect of Smoking Habits on the Efficacy of EGFR TKI Plus Anti-Angiogenic Agent in Advanced EGFR-Mutant NSCLC
- Smoking History and Overall Survival in Patients Receiving First-Line Pembrolizumab for Advanced NSCLC
- Impact of Smoking Status on the Efficacy of EGFR-TKI Plus Angiogenesis Inhibitor Combination Therapy in Advanced NSCLC